Core Viewpoint - The company, Zhongji Changshou Science (00767), plans to acquire 25% of the issued share capital of Asia Comprehensive Cell Bank Limited for an initial consideration of HKD 300 million, with the option to issue up to HKD 300 million in non-redeemable convertible bonds to finance the acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, and will be financed through a combination of cash and convertible bonds [1] - Asia Comprehensive Cell Bank Limited specializes in high-end customized stem cell and IPSC storage services, catering primarily to high-net-worth individuals in Hong Kong and mainland China [1] Group 2: Business Operations - The target company operates under various trade names, including Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, employing a team of registered doctors and laboratory technicians [1] - The company provides preclinical immunotherapy services and testing, indicating a focus on advanced medical solutions [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a high-growth potential business area [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increasing consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, and proactive health management strategies [1]

Core Viewpoint - Zhongji Changshou Science (00767) plans to acquire 25% of the issued share capital of Comprehensive Cell Bank Limited from China International Orthopedic Medical Group Co., Ltd. for an initial consideration of HKD 300 million, with the possibility of issuing redeemable convertible bonds up to HKD 300 million to finance this acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, with an initial payment of HKD 300 million [1] - The company will issue redeemable convertible bonds to cover the initial consideration, with a maximum amount of HKD 300 million [1] Group 2: Target Company Operations - The target company operates a boutique high-end customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to clients, particularly high-net-worth individuals in Hong Kong and mainland China [1] - The target company operates under the trade names of Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, staffed by registered doctors and laboratory technicians [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a new business area with significant growth potential [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increased consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, holistic health management, and proactive health management strategies [1]